Literature DB >> 2940332

Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan.

H Y Hsu, M H Chang, D S Chen, C Y Lee, J L Sung.   

Abstract

Hepatitis B virus (HBV) markers were studied by radioimmunoassays in serum samples of 1,200 (647 male, 553 female) apparently healthy children under 15 years of age in Taipei between June and October 1984. The prevalence rate of hepatitis B surface antigen (HBsAg) was 5.1% in infancy, increased to 10.7% between 1 and 2 years of age, and then remained constant at about 10% thereafter. The prevalence rate of surface antibody (anti-HBs), core antibody (anti-HBc), and seropositivity (at least one marker of hepatitis B detectable) were 39.0, 30.5, and 52.5%, respectively, in infancy, then decreased to 10.7, 14.3, and 17.9%, respectively, between 1 and 2 years of age. Thereafter, the antibody prevalence increased in parallel with age. By the age of 13-14 years, nearly half of the children were infected by HBV. The results suggested that in our children, most HBsAg carriers resulted from infections before 3 years of age, and HBV infections after 3 years of age infrequently resulted in a carrier state. One hundred (83.3%) of the 120 HBsAg-positive children had hepatitis B e antigen (HBeAg), indicating high prevalence in young asymptomatic HBsAg carriers. The prevalence rate of HBeAg tended to decrease with age and a reversed trend was observed with anti-HBe. Our study, just before our government extends mass hepatitis B vaccination program from newborns to children, provides background seroepidemiologic data of HBV infections in the healthy children in Taiwan.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2940332     DOI: 10.1002/jmv.1890180402

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  36 in total

1.  Presentation of autoantibody to proliferating cell nuclear antigen in patients with chronic hepatitis B and C virus infection.

Authors:  B S Tzang; T Y Chen; T C Hsu; Y C Liu; G J Tsay
Journal:  Ann Rheum Dis       Date:  1999-10       Impact factor: 19.103

2.  Cost-effectiveness analysis of prophylactic lamivudine use in preventing vertical transmission of hepatitis B virus infection.

Authors:  Hui-Fang Hung; Hsiu-Hsi Chen
Journal:  Pharmacoeconomics       Date:  2011-12       Impact factor: 4.981

3.  Profile of Ding-Shinn Chen.

Authors:  Philip Downey
Journal:  Proc Natl Acad Sci U S A       Date:  2007-09-17       Impact factor: 11.205

Review 4.  Chronic viral hepatitis.

Authors:  M H Chang
Journal:  Indian J Pediatr       Date:  1995 Nov-Dec       Impact factor: 1.967

5.  Different hepatitis B virus core gene mutations in children with chronic infection and hepatocellular carcinoma.

Authors:  Y-H Ni; M-H Chang; H-Y Hsu; D-J Tsuei
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

Review 6.  KASL clinical practice guidelines: management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2016-03-28

7.  Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation.

Authors:  Cheng-Yuan Peng; Chih-Bin Chen; Hsueh-Chou Lai; Wen-Pang Su; Po-Heng Chuang; Hong-Dar Isaac Wu; Long-Bin Jeng
Journal:  Hepatol Int       Date:  2010-12-16       Impact factor: 6.047

8.  Viral infection, human papillomavirus DNA, and cervical neoplasia.

Authors:  P Walker; J Giles; P Griffiths
Journal:  Br Med J (Clin Res Ed)       Date:  1988-04-16

9.  Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.

Authors:  Chieh-Lung Cheng; Sheng-Chuan Huang; Jia-Hong Chen; Chao-Hung Wei; Wei-Quan Fang; Tung-Hung Su; Chang-Tsu Yuan; Jia-Hau Liu; Ming-Kai Chuang; Hwei-Fang Tien
Journal:  Oncologist       Date:  2020-04-27

10.  Hepatitis B and C viruses are not risks for pancreatic adenocarcinoma.

Authors:  Ming-Chu Chang; Chien-Hung Chen; Ja-Der Liang; Yu-Wen Tien; Chiun Hsu; Jau-Min Wong; Yu-Ting Chang
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.